Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Siamak Daneshmand, MD
University of Southern California
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Radboudumc
Nijmegen, Netherlands
- University of Southern California Norris Comprehensive Cancer Center
Los Angeles, California, United States
- University of Chicago Medical Center
Chicago, Illinois, United States
- Johns Hopkins Hospital
Baltimore, Maryland, United States
- Columbia University Medical Center
New York, New York, United States
- Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2016
- Primary completion
- 2 May 2019
- Completion
- 2 May 2019
- Last update posted
- 18 Sept 2023
- Registered enrollment
- 23
- Registry id
- NCT02722538
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.